Drug Trial Radar · NCT00323856
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Apr 8, 2003
Primary completion
Dec 11, 2018
Study completion Dec 14, 2018
Sponsor
- Lead sponsor
- Grifols Biologicals, LLCIndustry
- Sponsor type
- Industry
- First posted
- May 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.
Conditions
- Severe Hemophilia A
Interventions
Alphanate SD/HTDrug
Plasma-derived preparation of Factor VIII
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Factor VIII (FVIII) Inhibitor DevelopmentTime frame: Up to Month 30
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Katedra i Klinika Hematologii Collegium Medicum UJ
Krakow, Poland
Oddzial Chorob Wewnetrznych i Hematologii
Poznan, Szkolna, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.